Preclinical characterization of anticancer gallium(III) complexes: solubility, stability, lipophilicity and binding to serum proteins.

@article{Rudnev2006PreclinicalCO,
  title={Preclinical characterization of anticancer gallium(III) complexes: solubility, stability, lipophilicity and binding to serum proteins.},
  author={Alexander V Rudnev and Lidia S. Foteeva and Christian R Kowol and Roland Berger and Michael A Jakupec and Vladimir B Arion and Andrei R Timerbaev and Bernhard K Keppler},
  journal={Journal of inorganic biochemistry},
  year={2006},
  volume={100 11},
  pages={
          1819-26
        }
}
The discovery and development of gallium(III) complexes capable of inhibiting tumor growth is an emerging area of anticancer drug research. A range of novel gallium coordination compounds with established cytotoxic efficacy have been characterized in terms of desirable chemical and biochemical properties and compared with tris(8-quinolinolato)gallium(III) (KP46), a lead anticancer gallium-based candidate that successfully finished phase I clinical trials (under the name FFC11), showing activity… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

Similar Papers

Loading similar papers…